Introduction to durvalumab (durvalumab) indication scope and applicable patient population

Durvalumab (Durvalumab) is a humanized immune checkpoint inhibitor that is an anti-PD-L1 (programmed death ligand-1) monoclonal antibody. It restores and enhances the patient's own immune system's ability to recognize and kill tumor cells by blocking the combination of PD-L1 with PD-1 and CD80, thereby achieving anti-tumor effects. The drug has shown good efficacy in the treatment of a variety of solid tumors and has become an important part of immunotherapy.

Currently, durvalumab has been approved by many countries and regions around the world. Its main indications include: consolidation treatment of patients with locally advanced unresectable non-small cell lung cancer (NSCLC) and first-line maintenance treatment of small cell lung cancer (SCLC). In addition, it is also used in the treatment of patients with urothelial cancer (bladder cancer), especially in advanced or metastatic patients who are unable to receive platinum-containing chemotherapy. The expanding indications demonstrate its broad application potential in the field of tumor immunotherapy.

In terms of applicable population, durvalumab is mainly targeted at patients with advanced or metastatic tumors that cannot be removed by surgery or have limited response to traditional chemotherapy. These patients often require new treatments to prolong survival and improve quality of life. Especially for those patients whose tumors express PD-L1, durvalumab may lead to better efficacy. In addition, the patient's overall health and immune function also influence the choice and effectiveness of treatment.

In summary, durvalumab, as an innovative immunotherapy drug, provides a new treatment option for patients with a variety of advanced solid tumors. Its indications cover many fields such as lung cancer and urothelial cancer, and is especially suitable for patients whose traditional treatments are ineffective. Before receiving treatment, patients should make reasonable choices under the guidance of a doctor based on their own specific conditions to ensure safe and effective medication.

Reference materials:https://www.imfinzi.com/

xa0